Skip to main content
Our Work

Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: A Workshop

Completed

Topics

The National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a workshop on September 10, 2024, they brought together diverse perspectives to examine the promising but understudied applications of GLP-1R agonists in neurological and psychiatric disorders. Experts reviewed the current knowledge and research gaps about how GLP-1R agonists work and evidence of their clinical efficacy for neurodegenerative diseases, substance use disorders, and pain. Attendees from academia, industry, government, and nonprofits also explored regulatory challenges/opportunities in repurposing these drugs for brain conditions.

About Past Events

Description

A planning committee of the National Academies of Sciences, Engineering, and Medicine will host a one-day public workshop that brings together leaders and experts from academia, industry, government, philanthropic foundations, and disease-focused non-profit organizations across disciplines (e.g., neuroscience, pharmacology, medicine, and endocrinology) to examine potential applications of glucagon-like peptide-1 receptor (GLP-1R) agonists in central nervous system disorders, such as dementia, Parkinson’s disease, substance and alcohol use disorders, and pain.
Invited presentations and discussions may:

  • Review the current state of knowledge regarding the mechanisms of action of GLP-1R agonists and their therapeutic applications across different disease areas.
  • Discuss available scientific evidence on the clinical efficacy of GLP-1R agonists, among other considerations, for treating various central nervous system disorders, including neurodegenerative diseases, and alcohol and substance use disorders, and for pain management.
  • Examine regulatory challenges and opportunities surrounding the application of GLP-1R agonists as therapeutic treatments for central nervous system disorders.
  • Highlight current research gaps and consider opportunities to move the field forward.

A planning committee will develop the agenda for the workshop, select and invite speakers and discussants, and moderate the discussions. Following the workshop, proceedings of the presentations and discussions will be prepared by a designated rapporteur in accordance with institutional guidelines.

Collaborators

Committee

Co-Chair

Co-Chair

Member

Member

Member

Member

Member

Member

Member

Member

Member

Member

Member

Download all bios

Sponsors

Acadia Pharmaceuticals

Alzheimer's Association

American Brain Coalition

American Neurological Association

Boehringer Ingelheim

BrightFocus Foundation

California Institute for Regenerative Medicine

Cerevel Therapeutics

Cohen Veterans Bioscience

Dana Foundation

Department of Health and Human Services

Department of Veterans Affairs

Eisai

Food and Drug Administration

Foundation for the National Institutes of Health

Gatsby Charitable Foundation

Harmony Biosciences

Janssen Research & Development, LLC

Karuna Therapeutics

Lundbeck Research USA, Inc.

Michael J. Fox Foundation for Parkinson's Research

National Center for Complementary and Integrative Health

National Eye Institute

National Institute of Environmental Health Sciences

National Institute of Mental Health

National Institute of Neurological Disorders and Stroke

National Institute on Aging

National Institute on Alcohol Abuse and Alcoholism

National Institute on Drug Abuse

National Institutes of Health BRAIN Initiative

National Multiple Sclerosis Society

National Science Foundation

One Mind

Paul G. Allen Frontiers Group

Simons Foundation

Takeda

The George & Anne Ryan Institute for Neuroscience at the University of Rhode Island

Wellcome Trust

Staff

Sheena Posey Norris

Lead

Eva Childers

Kimberly Ogun

Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.